Spinal muscular atrophy with respiratory distress type 1 associated with novel compound heterozygous mutations in IGHMBP2 : Differential diagnosis in a case with congenital diaphragm eventration

2018 ◽  
Vol 59 (1) ◽  
pp. 22-23
Author(s):  
Yoshitomo Yasui ◽  
Hitoshi Sato ◽  
Yo Niida ◽  
Miyuki Kohno
2018 ◽  
Vol 5 ◽  
pp. 2329048X1876981 ◽  
Author(s):  
Annie Ting Gee Chiu ◽  
Sophelia Hoi Shan Chan ◽  
Shun Ping Wu ◽  
Shun Hin Ting ◽  
Brian Hon Yin Chung ◽  
...  

The authors report a child with spinal muscular atrophy with respiratory distress type 1 (SMARD1). She presented atypically with hypothyroidism and heart failure due to septal defects that required early heart surgery and microcephaly in association with cerebral atrophy and thin corpus collosum. The subsequent asymmetrical onset of diaphragmatic paralysis, persistent hypotonia, and generalized muscle weakness led to the suspicion of spinal muscular atrophy with respiratory distress type 1. Sanger sequencing confirmed a compound heterozygous mutation in the Immunoglobulin Mu Binding Protein 2 (IGHMBP2) gene, with a known mutation c.2362C > T (p.Arg788*) and a novel frameshift mutation c.2048delG (p.Gly683A1afs*50). Serial nerve conduction study and electromyography confirmed progressive sensorimotor polyneuropathy and neuronopathy. In summary, this case report describes a child with spinal muscular atrophy with respiratory distress type 1 also with congenital cardiac disease and endocrine dysfunction, expanding the phenotypic spectrum of this condition. A high index of suspicion is needed in diagnosing this rare condition to guide the management and genetic counseling.


2006 ◽  
Vol 32 (11) ◽  
pp. 1851-1855 ◽  
Author(s):  
Alberto Giannini ◽  
Anna Maria Pinto ◽  
Giordano Rossetti ◽  
Edi Prandi ◽  
Danilo Tiziano ◽  
...  

2003 ◽  
Vol 54 (6) ◽  
pp. 719-724 ◽  
Author(s):  
Katja Grohmann ◽  
Raymonda Varon ◽  
Piroschka Stolz ◽  
Markus Schuelke ◽  
Catrin Janetzki ◽  
...  

2019 ◽  
Vol 520 (2) ◽  
pp. 341-346
Author(s):  
Monir Shababi ◽  
Caley E. Smith ◽  
Mona Kacher ◽  
Zayd Alrawi ◽  
Eric Villalón ◽  
...  

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Jianping Jiang ◽  
Jinwei Huang ◽  
Jianlei Gu ◽  
Xiaoshu Cai ◽  
Hongyu Zhao ◽  
...  

Abstract Background Spinal muscular atrophy (SMA) is a rare neuromuscular disorder threating hundreds of thousands of lives worldwide. And the severity of SMA differs among different clinical types, which has been demonstrated to be modified by factors like SMN2, SERF1, NAIP, GTF2H2 and PLS3. However, the severities of many SMA cases, especially the cases within a family, often failed to be explained by these modifiers. Therefore, other modifiers are still waiting to be explored. Case presentation In this study, we presented a rare case of SMA discordant family with a mild SMA male patient and a severe SMA female patient. The two SMA cases fulfilled the diagnostic criteria defined by the International SMA Consortium. With whole exome sequencing, we confirmed the heterozygous deletion of exon7 at SMN1 on the parents’ genomes and the homozygous deletions on the two patients’ genomes. The MLPA results confirmed the deletions and indicated that all the family members carry two copies of SMN2, SERF1, NAIP and GTF2H2. Further genomic analysis identified compound heterozygous mutations at TLL2 on the male patient’s genome, and compound heterozygous mutations at VPS13A and the de novo mutation at AGAP5 on female patient’s genome. TLL2 is an activator of myostatin, which negatively regulates the growth of skeletal muscle tissue. Mutation in TLL2 has been proved to increase muscular function in mice model. VPS13A encodes proteins that control the cycling of proteins through the trans-Golgi network to endosomes, lysosomes and the plasma membrane. And AGAP5 was reported to have GTPase activator activity. Conclusions We reported a case of SMA discordant family and identified mutations at TLL2, VPS13A and AGAP5 on the patients’ genomes. The mutations at TLL2 were predicted to be pathogenic and are likely to alleviate the severity of the male SMA patient. Our finding broadens the spectrum of genetic modifiers of SMA and will contribute to accurate counseling of SMA affected patients and families.


Sign in / Sign up

Export Citation Format

Share Document